RO24-7429 (TAT INHIBITOR) PILOT-- ORAL SOLUTION IN HIV POSITIVE PATIENTS

RO24-7429（TAT 抑制剂）试验——HIV 阳性患者的口服溶液

• 批准号: 3847419
• 负责人: PAUL S LIETMAN
• 金额: --
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3847419
• 关键词: AIDS therapy; HIV infections; antiAIDS agent; clinical trials; drug screening /evaluation; genetic transcription; human subject; human therapy evaluation; transcription factor; virus replication

The Human Immunodeficiency Virus (HIV) genome contains a number of genes that regulate viral replication. Control of the activity of these genes and their encoded proteins represents a potential target for development of new antiretroviral drugs. The TAT (transactivator of transcription of HIV) inhibitor, RO 24-7429, is the first compound for clinical testing that uses this approach for therapy of HIV infection.

人免疫缺陷病毒（HIV）基因组包含许多基因 调节病毒复制。控制这些基因的活性 它们的编码蛋白代表了开发的潜在目标 新的抗逆转录病毒药物。 TAT（转录剂的转录剂 HIV）抑制剂，RO 24-7429是临床测试的第一个化合物 这使用这种方法来治疗艾滋病毒感染。